The short version of AOD-9604 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-10-13. Anything still debated is marked as such rather than presented as settled.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
=== Language === Marain is the Culture's shared constructed language. The Culture believes the Sapir–Whorf hypothesis that language influences thought, and Marain was designed by early Minds to exploit this effect, while also "appealing to poets, pedants, engineers and programmers". Designed to be represented either in binary or symbol-written form, Marain is also regarded as an aesthetically pleasing language by the Culture. The symbols of the Marain alphabet can be displayed in three-by-three grids of binary (yes/no, black/white) dots and thus correspond to nine-bit binary numbers. Related comments are made by the narrator in The Player of Games regarding gender-specific pronouns, which Marain speakers do not use in typical conversation unless specifying one's gender is necessary, and by general reflection on the fact that Marain places much less structural emphasis on (or even lacks) concepts like possession and ownership, dominance and submission, and especially aggression. Many of these concepts would in fact be somewhat theoretical to the average Culture citizen. Indeed, the presence of these concepts in other civilisation signify the brutality and hierarchy associated with forms of empire that the Culture strives to avoid. Marain itself is also open to encryption and dialect-specific implementations for different parts of the Culture. M1 is basic Nonary Marain, the three-by-three grid. All Culture citizens can communicate in this variant. Other variants include M8 through M16, which are encrypted by various degrees, and are typically used by the Contact Section.
Sporadic (sCJD), caused by the spontaneous misfolding of the prion protein in an individual. This accounts for 85% of cases of CJD. Sporadic CJD can be further sub-classified by molecular profile into subtypes (MM1, MV2, etc.), which correlate with certain clinical-pathologic features. MM1 / MV1 Subtype: Clinical Features: Accounts for approximately 75% of sCJD cases. Characterized by rapidly progressive dementia, myoclonus, and typical EEG findings. Neuropathology: Synaptic-type PrPSc deposition predominantly in the cerebral cortex. Spongiform changes are widespread, with significant neuronal loss and gliosis. MM2 Subtype: MM2C (Cortical): Presents with a more prolonged disease course and prominent cortical involvement. Neuropathology reveals PrPSc deposits in the cortex with less spongiform change compared to MM1. MM2T (Thalamic): Rare; characterized by predominant thalamic involvement, leading to sleep disturbances and autonomic dysfunction. Neuropathology shows significant PrPSc deposition and neuronal loss in the thalamus. VV1 Subtype: Clinical Features: Rare; presents at a younger age with a slower disease progression. Neuropathology: Predominant cortical involvement with synaptic-type PrPSc deposition. VV2 Subtype: Clinical Features: Second most common subtype. Patients often present with ataxia and other cerebellar signs. Neuropathology: Significant PrPSc deposition in the cerebellum and basal ganglia, with prominent spongiform changes and neuronal loss. Familial (fCJD), caused by an inherited mutation in the prion-protein gene.
=== Dipeptides === The simplest peptide building blocks are dipeptides. Nanotubes formed from dipeptides are the widest among peptide nanotubes. An example of a dipeptide that has been studied is a peptide from the diphenylalanine motif of the Alzheimer's β-amyloid peptide. Dipeptides have also been shown to self-assemble into hydrogels, another form of nanostructures, when connected to the protecting group Fluorenylmethyloxycarbonyl chloride. Experiments focusing on the dipeptide Fmoc-Diphenylalanine have been conducted that have explored the mechanism in which Fmoc-diphenylalanine self-assembles into hydrogels via π-π interlocked β-sheets. Phenylalanine has an aromatic ring, a crucial part of the molecule due to its high electron-density, which favors self-assembly where the rings stack and enable the assembly to occur.
Sources: en.wikipedia.org
== Types == In 2017, 13 subtypes of EDS were classified using specific diagnostic criteria. According to the Ehlers–Danlos Society, the syndromes can also be grouped by the symptoms determined by specific gene mutations. Group A disorders are those that affect primary collagen structure and processing. Group B disorders affect collagen folding and crosslinking. Group C includes disorders of the structure and function of the myomatrix. Group D disorders are those that affect glycosaminoglycan biosynthesis. Defects in the complement pathway characterize Group E disorders. Group F are disorders of intracellular processes, and Group G is considered to be unresolved forms of EDS.
== Bibliography == Audi, G.; Kondev, F. G.; Wang, M.; et al. (2017). "The NUBASE2016 evaluation of nuclear properties". Chinese Physics C. 41 (3). 030001. Bibcode:2017ChPhC..41c0001A. doi:10.1088/1674-1137/41/3/030001. pp. 030001-1–030001-17 pp. 030001-18–030001-138, Table I. The NUBASE2016 table of nuclear and decay properties Beiser, A. (2003). Concepts of modern physics (6th ed.). McGraw-Hill. ISBN 978-0-07-244848-1. OCLC 48965418. Hoffman, D. C.; Ghiorso, A.; Seaborg, G. T. (2000). The Transuranium People: The Inside Story. World Scientific. ISBN 978-1-78-326244-1. Kragh, H. (2018). From Transuranic to Superheavy Elements: A Story of Dispute and Creation. Springer. ISBN 978-3-319-75813-8. Zagrebaev, V.; Karpov, A.; Greiner, W. (2013). "Future of superheavy element research: Which nuclei could be synthesized within the next few years?". Journal of Physics: Conference Series. 420 (1) 012001. arXiv:1207.5700. Bibcode:2013JPhCS.420a2001Z. doi:10.1088/1742-6596/420/1/012001. ISSN 1742-6588. S2CID 55434734.
The Houthis joined the war on 28 March launching a ballistic missile towards Israel while stating that they had launched ballistic missiles targeting "sensitive" military sites in Israel; the missile was intercepted and no casualties were reported. The Houthis subsequently launched a second missile at Eilat. In response, the internationally recognized Yemeni government condemned Iran's "frequent attempts to drag Yemen" into conflict "through its terrorist militias". On the same day, 2,500 US marines from the 31st Marine Expeditionary Unit arrived in the Middle East, expected to be part of US efforts to open the Strait of Hormuz. US Central Command (CENTCOM) stated that it had struck over 11,000 targets in Iran since the beginning of the war. On 28 March, joint US–Israeli airstrikes severely damaged several residential and civilian facilities, including the Iran University of Science and Technology. In response, Iran threatened to attack Israeli and American colleges across the Middle East. Airstrikes also struck a 10,000-cubic-metre (350,000 cu ft) water reservoir in Haftkel, in Khuzestan province. An Iranian missile struck a chemical plant in the Ne'ot Hovav industrial zone, injuring one person and causing fears of a hazardous leak. A convoy of the Iraqi Popular Mobilization Forces was seen entering Khorramshahr in southwestern Iran. Eleven-year-old child soldier Alireza Jafari was killed in an Israeli drone strike "while serving" at a checkpoint on a Tehran highway; Amnesty International called the organized Iranian recruitment of children as young as Jafari a war crime.
Agnolín, Bogan & Lucero (2026) consider Balaena pampaea, Notiocetus romerianus and N. platensis to be nomina dubia, interpreting the fossil material of N. platensis as remains of an indeterminate baleen whale, and interpreting fossils of B. pampaea and N. romerianus as remains of an indeterminate balaenid. Lambert et al. (2026) report shark feeding traces on bones of cetacean specimens from the Pliocene Kattendijk Formation (Belgium), including evidence of a bluntnose sixgill shark feeding on a right whale Balaenella brachyrhynus and evidence of Carcharodon plicatilis feeding on a member of the genus Casatia. López-Galán, Ferrón & Botella (2026) study ecomorphological variation of extant and extinct filter-feeding cetaceans, pachycormiform fishes and selachians, interpreting members of the three groups as repeatedly converging toward analogous functional designs, but also interpreting their convergent evolution as influenced by lineage-specific constraints.
Sources: en.wikipedia.org
== Physiology == During digestion, fats, or triglycerides(TGs), are enzymatically catabolized by lipases into two fatty acids and a monoglyceride molecule. Those components are then transported across the enterocyte membrane as micelles and reformed into triglycerides once across the membrane. Once transported to the ER the triglycerides are incorporated into pre-chylomicrons which are made up of TGs, cholesterol, and phospholipids. The pre-chylomicrons are then packaged into PCTV to be transported to the Golgi apparatus for additional maturation prior to exocytosis into the lymphatic system. From the lymphatic system, they enter general circulation, where they are produced in various forms that can be absorbed by bodily tissues and metabolized or stored by adipose tissue. Before the PCTV leaves the ER, it is incorporated into a COPII coatomer of five proteins. The PCTV undergoes a similar mechanism for budding as normal COPII transport vesicles. Though PCTV does not require COPII coatomer proteins for budding from the ER, association with the coatomer is necessary for docking and fusion with the cis-golgi network. In chylomicron retention disease, the PCTV vesicles are competent for budding from the ER membrane but are defective for fusion with the cis-golgi body. Sar1B is a GTPase and one of the five proteins of the COPll coatomer. A mutation in the sar1B gene and subsequently the sar1B protein are the common genetic origins of chylomicron retention disorder.
==== Intercity coaches ==== Intercity bus service to and from Penn Station is provided by Vamoose Bus, Tripper Bus, and Go Buses. Vamoose Bus runs buses from a stop near Penn Station to Bethesda, Maryland; Arlington, Virginia; and Lorton, Virginia. Tripper Bus runs buses from a stop near Penn Station to Bethesda, Maryland and Arlington, Virginia. Go Buses runs buses from a stop near Penn Station to Newton, Massachusetts and Cambridge, Massachusetts. In 2021, the private parking lot at 300 West 31st Street (the southwest corner of 8th Avenue) was established as a major Midtown Manhattan hub stop for FlixBus. Most intercity and commuter bus services to and from midtown Manhattan use the Port Authority Bus Terminal, located approximately 0.5 miles (0.8 kilometers) to the north of Penn Station.
== Clinical significance == A change in the structure of a conjugated protein can change the function and result in a number of different diseases. For example, changes in the primary structure of hemoglobin causes sickle cell anaemia and thalassemia, both of which change the way oxygen is transported in the bloodstream. Moreover, lipoproteins' level abnormalities can cause or worsen atherosclerosis as the amounts of cholesterol increase in the artery walls. Glycoproteins can also be used as markers for certain diseases. Changes in glycosylation are associated with some cancers, inflammation, and autoimmune diseases. Anemia and Wilson's disease can also be caused by mutations in metalloproteins as they are responsible for transporting metal ions. In medicine, conjugated protein can be used in vaccines. For example, polysaccharide-protein conjugate vaccines can increase the effectiveness of vaccines.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.